
Today on Pharmaceutical Processing
Novo Nordisk announces $507M GLP-1 manufacturing expansion in Ireland
Novo Nordisk today announced plans to invest €432 million ($507 million) in its facility in Monksland, Athlone, Ireland. The Danish pharmaceutical giant plans to add significant additional manufacturing capacity for current and future GLP-1 treatments. According to Novo Nordisk, the expansion of the tabletting facility further reinforces its long-term commitment to Ireland and global healthcare…Novartis to build new radioligand therapy manufacturing site in Texas
Novartis announced today that it plans to establish a new radioligand therapy (RLT) manufacturing site in Denton, Texas. The purpose-built RLT site will mark Novartis’ fifth in the U.S. and first manufacturing facility in Texas. It comes as part of a planned $23 billion investment across the U.S. Novartis has, in the past couple of…Sponsored Content See More >
Regulatory See More >

Putting patients first in clinical trials
Clinical trials offer clinicians a unique opportunity to lead advances in medicine, granting access to cutting-edge therapies that address unmet patient needs. They are a cornerstone of clinical practice that enhance patient outcomes, particularly for those with complex or refractory cases who have exhausted standard treatment options. Clinicians understandably prioritize the well-being and interests of…

Confidently navigate the transition from bench to batch

FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension

Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths

Eicos Sciences’ FDA-approved Aurlumyn promises to drastically reduce frostbite amputations
Learn how to rapidly develop smart and sustainable engineering and production processes See More >

Personalized medicine: advanced technology is saving lives
The concept of a “batch size one” in pharmaceutical manufacturing is closer than ever. There are companies advancing cell therapies in which body cells are used to heal or support the individual patient. These cells are manipulated or edited to change certain biological characteristics before being transferred to the patient. Personalized medicine is truly about…
Facility See More >

MGS opens 300,000-square-foot Wisconsin facility to scale drug delivery device manufacturing
Healthcare CDMO manufacturer MGS has brought a 300,000 square foot drug delivery device manufacturing facility online in Richfield, Wisconsin. The move expands U.S. production capacity as demand for complex combination products strains available cleanroom capacity . FDA approved a record number of combination products in recent years, and the 505(b)(2) pathway has made device-drug combos…
Supply Chain See More >

BioDuro, Cenra launch joint venture for API manufacturing
BioDuro announced that it established a joint venture with Cenra API Solutions, also as known as Chunghwa Chemical Synthesis & Biotech Co. The joint venture aims to combine the services of the CRDMO and a pharmaceutical chemical manufacturer. They hope to add significant commercial-scale active pharmaceutical ingredient (API) manufacturing capacity at Cenra’s campus in Taipei, Taiwan,…
Recalls See More >

Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Japanese health authorities searched a Kobayashi Pharmaceutical factory in Japan following reports of five deaths related to dietary supplements, Reuters reports. The plant inspection in western Japan is the second in recent days as health authorities inspected the company’s Osaka facility. In addition to the five reported deaths, there have been more than 100 hospitalizations…


































